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Treating azotemia-induced anemia with erythropoietin im-
proves diabetic eye disease.
Background. Coincidental with the pandemic growth of dia-
betes as the prime cause of end-stage renal disease (ESRD),
blindness attributable to diabetic retinopathy has become a
major concern for all those involved in the care of diabetic
ESRD patients. Vision loss is linked to progression of prolifera-
tive retinopathy and macular edema.
Methods. Extracted from a study of azotemic anemic pre-
ESRD patients treated with erythropoietin, a cohort of five
diabetic subjects was reassessed in terms of stability of renal
function, changes in blood rheology, and course of diabetic
eye disease.
Results. All subjects reported subjective improvement in
well-being, including enhanced effort tolerance following an
increase in hematocrit from a baseline level of to 29.6  2.0%
to a level of 39.5  2.4% after one year of treatment with
erythropoietin (P0.0005). Neither hypertension nor deterio-
ration of renal function was noted in any subject. Three patients
with macular edema evinced substantive improvement-based
stable vision and documented resolution noted in flourescein
angiography.
Conclusion. Erythropoietin treatment of anemic azotemic
diabetic patients is well tolerated. In a small observational
retrospective study of three patients with macular edema, re-
tention of vision and resolution of exudates was noted.
As a consequence of its myriad, duration-related, multi-
system complications, diabetes mellitus, as an emerging
pandemic, is a dominant concern of internists, cardiolo-
gists, nephrologists, and ophthalmologists. Among United
States adults, the prevalence of diagnosed diabetes in-
creased 49% from 1990 to 2000. In the United States in
2003, an estimated 798,000 people will be informed of
diagnosed diabetes, while 187,000 people will die from
Key words: diabetes, nephropathy, erythropoietin, hypoxia, pseudo-
hypoxia, retinopathy, macular edema.
Presented at the Conference: Management of Comorbidities in Kidney
Disease, at the Long Island College Hospital, Brooklyn, New York,
May 30, 2003.
 2003 by the International Society of Nephrology
S-57
diabetes. Depending on age, race, and gender, diabetes
in 1996 ranked from 8th (white men aged 45 to 65 years)
to 4th (black women aged 45 years and over) leading
cause of death [1]. In 2003, an estimated 135 million
people worldwide will have diabetes, with an anticipated
growth to 300 million by 2025.
Accompanying their greater longevity, the majority of
treated diabetic ESRD patients suffer serious eye dis-
ease, inducing progressive loss of vision. “At least 50
million people are likely to have diabetic retinopathy
and this number is projected to double by the year 2025
if no major control activity is developed.”[2]
Diabetes mellitus is the leading cause of end-stage
renal disease (ESRD) in the United States (US), Japan,
and most nations in industrialized Europe. As tabulated
in the latest United States Renal Data System (USRDS)
Report (2002), of 96,192 patients begun on therapy for
ESRD during 2000, 41,772 (43.4%) had diabetes, an inci-
dence rate of 145 per million population [3]. Health care
expenditures for diabetes in the United States amount
to a minimum of $100 billion and may reach $150 billion
annually [4].
Reflecting their relatively higher death rate compared
to other causes of ESRD, the prevalence of United States
diabetic ESRD patients on December 31, 2000 was 34%
(131,173 of 378,862 patients). Both glomerulonephritis
and hypertensive renal disease rank below diabetes in
frequency of diagnosis among new ESRD patients, sub-
stantiating the contention of Mauer and Chavers [5] that
“diabetes is the most important cause of ESRD in the
Western world.”
Diabetes is the leading cause of new cases of blindness
among adults 20 to 74 years old. Diabetic retinopathy
causes 12,000 to 24,000 new cases of blindness each year.
The remarkable efficacy of laser photocoagulation in
forestalling irreversible vision loss in diabetes bonds oph-
thalmologist and nephrologists as cotherapists coping
with what has been termed the diabetic renal-retinal
syndrome [6]. Success in reducing the risk of blindness
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by modern interventive laser surgery has been remark-
able. For example, in the Newcastle District in the
United Kingdom, where a retinal screening program has
been running since 1986, “the rates of blindness and
partial-sightedness are less than one-third of those re-
ported in surveys prior to 1997.”[7] In this report, we
recount our experience, mainly anecdotal and observa-
tional, in assessing the response of eye disease in a pilot
population of anemic azotemic diabetic patients under
treatment with erythropoietin.
METHODS
Subjects for study of the effect of erythropoietin on
the anemia of renal insufficiency were solicited from
the renal clinic of University Hospital of Brooklyn. The
study was approved by the Institutional Review Board.
All subjects gave written informed consent. Adult sub-
jects, including those with diabetes, who had anemia
attributed to renal insufficiency, after confirmation of
normal iron stores, were treated with erythropoietin.
Inclusion criteria included anemia due to causes other
than kidney disease, absence of gastrointestinal and uri-
nary blood loss, and a serum creatinine concentration
of between 2.0 and 5.0 mg/dL. Diabetic persons were
admitted for study. Exclusion criteria included absence
of concurrent disorders (malignancy, progressive cere-
brovascular disease) likely to progress within one year
to life-threatening degree. Of the total group of 40 sub-
jects in the trial, five diabetic patients met the entrance
criteria. The effect of erythropoietin on anemia in these
five diabetic subjects has previously been presented, in
part, without peer review [8]. Assessment of the effect
of erythropoietin on macular edema in the three patients
cited below has been previously reported in part [9].
Upon initiation of study, each diabetic subject had
a physical examination, measurement of seated blood
pressure, ophthalmologic evaluation including retinal
photography and, where indicated, fluorescein angiogra-
phy of the retina, and an electrocardiogram. Patients
were followed on an ambulatory basis, at weekly to
monthly intervals determined by their course and com-
plications. At each visit, a physical examination, includ-
ing seated blood pressure measurement, was performed
and a hemogram and chemical screen were obtained.
End points for the trial were either death or progression
to ESRD.
Erythropoietin prepared by the Amgen Corporation
(Thousand Oaks, Calif, USA) and provided by Ortho
Pharmaceutical Corporation (Raritan, NJ, USA) was ad-
ministered intravenously in doses of 50 to 150 U/kg 3
times weekly until the mean hematocrit increased to
40%. Maintenance doses of erythropoietin were given
to sustain the hematocrit above 32%. Dietary protein
was restricted to 60 g/day. Antihypertensive and diuretic
medications were continued, as needed, in the judgment
of the primary nephrologist. Metabolic control of hyper-
glycemia was optimized using multiple daily finger-stick
glucose measurements in conjunction with fractional
doses of insulin or oral hypoglycemic agents.
The viscosity of an aliquot of heparinized venous
whole blood or plasma was determined with a LTV-CP
II Wells-Brookfield cone plate viscometer (Brookfield
Engineering Laboratories, Stoughton, MA, USA) at
37C as detailed by Wells et al [10]. Viscosity is expressed
in units of milli-pascal.second (mPas). Blood viscosity
was measured at high (230 s1) and low (23 s1) rates of
shear (4.35  0.53 and 6.83  0.79 mPas), respectively,
and plasma viscosity (230 s1) of 1.57  0.11 mPas for
high and low rates of shear, respectively. All measure-
ments were made in duplicate. Instrument accuracy and
precision was checked daily by repeated measures of
viscosity of distilled water and standard fluids (with vis-
cosities in the range of human blood) supplied by Brook-
field Engineering Laboratories. All measurements were
made within 2 hours of venesecion. For comparison with
a control population of anemic, but not azotemic sub-
jects, normal blood was diluted to lower hematocrits by
adding autologous plasma to attain a hematocrit of 30%.
The subset of three diabetic women found to have
macular edema were evaluated by a single ophthalmolo-
gist (D.H.B.). The course of their macular edema de-
scribed herein reflects the retrospective collection of a
clinical experience rather than a prospective study. Lack-
ing concurrent control groups, and with groups of only
five azotemic diabetics, including three individuals with
macular edema, statistical analysis of treatment groups
was not conducted. A comparison of pre-erythropoietin
and post-erythropoietin values in the five predialysis azo-
temic diabetic subjects is provided in Table 1.
RESULTS
There were five azotemic diabetic subjects treated for
anemia with erythropoietin. All five subjects remarked
on substantially improved well-being and greater toler-
ance for effort as their red cell mass (hematocrit) in-
creased. Urine protein excretion was not altered over
the course of study. One patient was hospitalized during
the year because of transient hyperkalemia attributed to
treatment with the angiotensin-converting enzyme inhib-
itor enalapril. There were no cardiovascular or cerebro-
vascular events in any of the five subjects. Mean systolic
and diastolic blood pressures were unchanged. None of
the patients were catabolic although azotemic; mean
body weight at the start (76.9  19.7 kg) was unchanged
after one year (76.3  19.7 kg). Mean serum creatinine
concentration was unchanged from study initiation (3.5
0.3 mg/dL) to study completion (3.7  0.3 mg/dL) after
one year.
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Table 1. Anemic predialysis azotemic diabetic patients treated with erythropoietin for one year (N  5)
Serum creatinine Blood viscosity Blood viscosity Plasma viscosity Blood pressure
Hematocrit % mg/dL 230 s1 23 s1 230 s1 mm Hg
Pre-erythropoietin 29.62.0 3.50.4 3.620.32 4.960.98 1.550.16 149.0/87.8
Post-erythropoietin 39.52.4 3.70.4 4.270.28 6.990.88 1.600.07 149.0/76.0
P 0.005 NS 0.001 0.001 NS NS
Results expressed as mean standard deviation; NS  not significant.
Fig. 1. Fluorescein angiogram of right eye (mid-venous phase) in Case
1 prior to treatment showing moderate intensity leakage from neovascu-
lar frond at the disc and diffusely at the macula (arrow).
Viscosity of whole blood and plasma at baseline level
and after treatment with erythropoietin for one year
are shown in Table 1. Whole blood viscosity for diluted
“normal” blood with hematocrit reduced to 30% was
3.49  0.27 and 5.05  0.63 mPas for high and low rates
of shear, respectively. Plasma viscosity was unchanged
throughout the course of observation. Whole blood vis-
cosity increased with the rise in hematocrit as measured
at both shear rates. There were no changes in plasma
lipids or serum protein concentration throughout the
study.
Summative data on the three patients who evinced im-
provement in macular edema after treatment with eryth-
ropoietin is given.
Case 1
A 63-year-old hypertensive woman with type 2 diabe-
tes who had azotemia (serum creatinine of 3.7 mg/dL)
and anemia (hematocrit of 22%) attributed to her kidney
disease was evaluated for deteriorating visual acuity. At
initial examination, the blood pressure was 150/90 mm Hg,
and the visual acuity was 20/200 in the right eye and
20/20 in the left eye. Funduscopic examination showed
a dense lipid exudate at the foveal center in the right
eye assigned a grade of 5 (Fig. 1A) according to the
Early Treatment Diabetic Retinopathy Study (ETDRS)
Fig. 2. Fluorescein angiogram of right eye (mid-venous phase) in Case
1 eight months later, after the hematocrit had been increased by treat-
ment with erythropoietin, demonstrating little or no leakage (arrow)
with the identical array of laser marks as the pretreatment angiogram.
[11]. Treatment with erythropoietin at a dose of 4000
IU injected subcutaneously twice weekly was begun. The
patient was also treated with tolazamide, metolazone,
furosemide, and lisinopril. After eight months of treat-
ment with erythropoietin, the hematocrit increased to
33%, the visual acuity in the right eye improved to 20/60,
and funduscopic examination showed complete resolu-
tion of the foveal hard exudates with an ETDRS grade
of 3. Repeat fluorescein angiography (Fig. 2) confirmed
the absence of new leakage and a stable pattern of non-
perfusion found on the first study. During the interval
between Figures 1 and 2, the blood pressure and serum
lipid profile were stable, and no laser treatments were
given.
Case 2
A 60-year-old formerly hypertensive woman with type 2
diabetes on maintenance hemodialysis because of dia-
betic nephropathy had severe visual loss with diminished
visual acuity of 20/400 due to diabetic retinopathy. The
right eye had extensive vitreous hemorrhage and the left
eye had parafoveal hard exudates and macular edema
designated ETDRS fundus photo grade 5. Fluorescein
angiography was not attempted because of the patient’s
prior anaphylactic reaction to fluorescein dye one year
earlier when panretinal photocoagulation had been per-
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formed for proliferative retinopathy. The blood pressure
was 110/70 mm Hg and the hematocrit was 21%. Treat-
ment with erythropoietin was initiated at a dose of 4000
IU injected subcutaneously twice weekly. The patient
was also treated with insulin and calcium carbonate.
After six months of erythropoietin injections, the hema-
tocrit increased to 31%, the blood pressure remained
normal, and the visual acuity had improved to 20/200
while fundoscopy indicated an ETDRS photo grade 4.
No laser treatment was administered.
Case 3
A 55-year-old hypertensive woman with type 1 diabe-
tes undergoing maintenance hemodialysis because of di-
abetic nephropathy had visual acuity of 20/50 in the right
eye and 20/40 in the left eye. Funduscopic examination
showed photocoagulation scars in the right eye and para-
foveal hard exudates and an old laser scar in the left eye
designated as ETDRS fundus photo grade 5. Fluorescein
angiography showed focal non-perfusion and mild leak-
age. The blood pressure was 149/92 mm Hg and the
hematocrit was 24%. A regimen of insulin, furosemide,
and metolazone was established and maintained over
the course of study. Erythropoietin treatment was started
at a dose of 4000 IU injected subcutaneously twice
weekly. Eleven months later, the hematocrit increased
to 32%, the patient’s visual acuity improved to 20/40 in
the left eye with substantial resorption of the macular
edema and hard exudates equivalent to ETDRS fundus
photo grade 3. Throughout these 11 months, blood pres-
sure was unchanged and no laser therapy was adminis-
tered. Repeat fluorescein angiography demonstrated no
change in the leakage pattern and no further decrease
in microcirculatory perfusion.
DISCUSSION
Erythropoietin is a remarkably safe and effective
means of correcting azotemic anemia in patients under-
going maintenance hemodialysis [12, 13]. Over the past
five years, administration of erythropoietin in azotemic
patients prior to the need for dialytic therapy has, by
consensus, become standard therapy [14]. Initial fear that
raising the hematocrit, thereby inducing an increased
blood viscosity, would accelerate the rate of decline of
renal function in azotemic patients was muted by consis-
tently favorable clinical experience [15, 16].
Macular edema, the most common finding in diabetic
persons losing visual acuity, usually is the consequence
of focal, and rarely diffuse, capillary leakage [17]. Retinal
thickening, the main associated finding in macular edema,
correlates with hard exudates [18] and capillary focal
leakage. Consisting mainly of polyunsaturated fats de-
posited in the outer plexiform layer of the retina, hard
exudates are derived from hyperpermeable microaneur-
ysms [19]. Hard exudates may resorb spontaneously or
after treatment of hypertension and uremia. Focal laser
treatment by sealing incompetent capillary microaneur-
ysms may reduce focal leakage promoting resorption
of hard exudates, thereby stabilizing visual acuity [20].
Bresnick [21] theorizes that the frequency of diabetic
macular edema is reduced when hypertension is treated,
but the relationship between blood lipids [22] and macu-
lar edema and hard exudate production is unclear [23].
Lacking a literature timeline connoting the natural
history of macular edema in diabetic individuals with
renal insufficiency, we utilized the charts of eight historic
“control” diabetic azotemic patients found to have macu-
lar edema, discerning that none evinced either resolution
of exudates or improvement in visual acuity over any
interval of observation. So-called residual hard exudates,
as found in Cases 1, 2, and 3, may persist without evi-
dence of vascular incompetence after maximal laser pho-
tocoagulation of the retina.
In our three cases, blood pressure, serum lipid levels,
and degree of retinal angiopathy, as judged by fluores-
cein angiography, were unchanged when the hematocrit
increased during erythropoietin treatment. Blindness is
no longer unstoppable in long-term diabetes. What was
previously considered the inexorable conclusion of a
poorly understood disease has been transformed into a
treatable disorder with an encouraging and consistently
improving outcome [24].
Retinal neovascularization is thought to follow the
release of angiogenic factors (vasoformative factors) by
an ischemic and hypoxic retina [25]. While the patho-
physiologic events leading to angiogenesis are obscure
[26], antiangiogenic agents are under evaluation as a
means of arresting retinal neovascularization [27]. De-
creased transcutaneous oxygen tension was measured in
119 diabetic subjects by an Oxymonitor (PPG Biomedi-
cal Systems, La Jolla, CA, USA) at 45C at the dorsum
of the foot [28]. In this study, tissue hypoxia was found
to precede clinical signs of angiopathy while correlating
with abnormal microrheologic parameters including
plasma viscosity, red cell aggregation times, disaggrega-
tion threshold, and red cell aggregate structure index.
Tissue hypoxia, specifically arterial wall hypoxia inde-
pendent of insulin treatment is proposed by Santilli, Fie-
gel, and Knighton [29] as an initiator and continuing
stimulus for atherosclerotic vascular occlusive disease in
diabetes. Williamson et al [30] use the term “pseudohyp-
oxia” to characterize the vasodilation and increased
blood flow characteristic of the early vascular response
to acute hyperglycemia that in hypoxic tissues is linked
with impaired oxidation of NADH to NAD, resulting
in an increased ratio of NADH/NAD. An increased
cytosolic ratio of free NADH/NAD caused by hyper-
glycemia is typical of poorly controlled diabetes and
mimics the effects of true hypoxia on vascular and neural
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function, promoting diabetic complications. These effects
are postulated to stimulate production of superoxide
anion and increased nitric oxide formation.
From an obverse perspective of the pathogenesis of
diabetic complications, it is pertinent that, based on the
electrophysiologic measurement of ischemic conduction
failure in the median nerve of diabetic subjects, Hampton
et al [31] suggest that hypoxia contributes to resistance
to ischemic conduction failure, a characteristic feature
of diabetic neuropathy. Consistent with this observation
is the report of Low et al [32] that in induced diabetic
rats, hyperbaric oxygenation partially reversed the neu-
ropathy of chronic diabetes. Supportive of the case for
hypoxia as a pathogenetic mechanism in diabetes is the
finding that hyperbaric oxygen heals otherwise hopeless
foot ulcers in diabetic individuals by enhancing oxygen-
ation of affected tissues while accelerating collagen pro-
duction, thereby enhancing tissue repair.
Our experience substantiates an overall benign course
in azotemic individuals with raised hematocrits, specifi-
cally the absence of cerebrovascular or cardiovascular
complications attributed to an erythropoietin-induced
increased blood mass. Indeed, we consistently note stable
renal function and patients report marked clinical im-
provement for at least the initial year of erythropoietin
therapy. Reconstruction of the time course of renal func-
tional deterioration in diabetic nephropathy will be nec-
essary to reflect the stability of diabetic patients who, in
the pre-erythropoietin era, might have been expected
to lapse into ESRD. Whether relative serum creatinine
levels in our outpatient group reflect what may or can
be accomplished in the overall population of azotemic
diabetic patients followed prospectively is under active
study in the duration of their hospitalizations while de-
laying the need for maintenance dialysis.
The pathogenesis of diabetic complications is debated—
hyperglycemia [33], growth factors [34], vascular defects
[35], and hemodynamic perturbations [36] are proposed
as primary factors leading to microvasculopathy. Over
the past five years, growing evidence supports the hy-
pothesis that hypoxia, at the organ, tissue, and/or cellular
level contributes to progression of tissue injury in dia-
betic individuals [30]. Brownlee, reviewing the molecular
cell biology of diabetes-specific microvascular disease,
including retinopathy and nephropathy, proposes that
the underlying mechanism is “a single hyperglycemia-
induced process of overproduction of superoxide by the
mitochondrial electron-transport chain [37].” If this think-
ing is correct, raising tissue oxygen tension might slow
the course of microvasculopathic complications. Increas-
ing the blood hemoglobin level by administration of re-
combinant erythropoietin is one means of improving ox-
ygen carriage to peripheral tissues.
In the present report, erythropoietin was administered
to five anemic azotemic diabetic subjects for one year
to assess the effect of increasing red cell mass on clinical
well-being and the course of renal functional decline.
None of the subjects manifested worsened hypertension,
cerebrovascular or cardiovascular complications, despite
an increase in mean hematocrit from a baseline of 29.6%
to 39.5%. The serum creatinine concentration after one
year of treatment with erythropoietin was 3.7 mg/dL,
which was unchanged from the baseline value of 3.5
mg/dL. Plasma viscosity remained constant as red cell
mass increased. Although the viscosity of whole blood
rose as the hematocrit increased, it was within the range
of normal blood viscosity for an equivalent hematocrit.
The favorable impact of erythropoietin treatment on
three diabetic subjects who had macular edema and ane-
mia is described. One hypothesis to explain the benefit
of a raised hematocrit on both diabetic nephropathy
and retinopathy is that the metabolic, hormonal, and
hemodynamic components of the diabetic syndrome, in
concert, produce tissue and cellular hypoxia that is amel-
iorated in part by the greater oxygen-transporting capac-
ity of a raised red cell mass. The pseudohypoxia of diabe-
tes may be implicated in the pathogenesis of diabetic
neuropathy, retinopathy, muscular dysfunction, and ne-
phropathy.
Nitric oxide (NO) and its stable end products, nitrite
and nitrate, induce oxidative stress in the angiogenic
process underlying proliferative diabetic retinopathy and
macular edema. Both vascular endothelial growth factor
(VGEF) and NO are “strikingly higher” than normal in
the vitreous fluid of patients with proliferative diabetic
retinopathy [38]. Confirming this indictment of oxidative
stress as predisposing to diabetic eye disease, Noma et al
[39] found that the concentrations of VEGF in aqueous
humor and vitreous fluid correlate (P  0.001) with the
severity of diabetic retinopathy, as do the concentrations
of endostatin (P  0.007). Completing the linkage, Fu-
natsu et al [24] reported that both VEGF and endostatin
levels in the vitreous fluid of patients with proliferative
diabetic retinopathy correlate with the outcome of vitre-
ous surgery and the prognosis for retention of sight.
Confounding acceptance of the preceding argument fa-
voring NO as a toxic factor are opposing experiments
suggesting that diabetic retinopathy is a condition caus-
ing a “risk of NO deficiency [40].”
A rationale for administration of erythropoietin to
anemic diabetic subjects cannot be based on an absolute
deficiency of this hormone. Indeed, erythropoietin activ-
ity in plasma, as assessed in posthypoxic polycythemic
mice, is higher in diabetic individuals than in clinically
healthy subjects [41]. Individuals with type 1 diabetes
are not deficient in erythropoietin synthesis [42]. As is
true for the apparently “normal” insulin level typically
found in type 2 diabetes even in the presence of hypergly-
cemia, a “normal” erythropoietin level in an anemic dia-
betic subject may be disproportionately low for the actual
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red cell mass. Just as the blood sugar falls with exogenous
insulin treatment in the hyperglycemia of type 2 diabetes,
so does the hematocrit rise in azotemic diabetic subjects
with purportedly “normal” endogenous erythropoietin
secretion.
Our limited evaluation of the effect of erythropoietin
on the course of eye disease in azotemic diabetic persons
supports three main inferences: (1) Erythropoietin is
well tolerated without major complication; (2) anemic
azotemic diabetic patients respond promptly with a vig-
orous increase in red cell mass to doses of erythropoietin
that are effective in nondiabetic azotemic persons; and
(3) an increased hematocrit may slow the progression
of diabetic nephropathy and improve visual acuity due
to resolution of macular edema in diabetic retinopathy.
We emphasize that our inferences lack comparison with
an untreated (control) population of persistently anemic
azotemic diabetic patients, who would presently repre-
sent questionable ethical practice of nephrology.
Growing evidence supports the prevalent hypothesis
that hypoxia, at the organ, tissue, and/or cellular level
contributes to progression of retinal injury in diabetic
individuals. If this thinking is correct, raising tissue oxy-
gen tension might slow the course of microvasculopathic
complications. Increasing the blood hemoglobin level
by administration of recombinant erythropoietin is one
means of improving oxygen carriage to peripheral tis-
sues. As remarked by Sinclair, DelVecchio, and Levin
[43] in their insightful contemporary review, however,
“The postulated mechanisms by which erythropoietin
treatment of anemia improves diabetic retinopathic le-
sions and slows the time course of retinopathy progres-
sion are many and varied. …there are no large studies
specifically addressing diabetic retinopathy and correc-
tion of anemia.”
CONCLUSION
We described the encouragingly favorable impact on
diabetic eye disease in a preliminary trial of erythropoie-
tin to determine the effect of increasing red cell mass on
the course of eye and kidney complications in azotemic
diabetic subjects.
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